Patrick Bolger
University of Rochester
2 Papers
Patrick Bolger is an academic researcher from University of Rochester. The author has contributed to research in topics: Randomized controlled trial & Placebo. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
Tanya Simuni,Brian K. Fiske,Kalpana Merchant,Christopher S. Coffey,Elizabeth A. Klingner,Chelsea Caspell-Garcia,David-Erick Lafontant,Helen Matthews,Richard K. Wyse,Patrik Brundin,David Simon,Michael A. Schwarzschild,David Weiner,Jaime Adams,Charles S. Venuto,Ted M. Dawson,Liana Baker,Melissa Kostrzebski,Tina Ward,Gary Rafaloff,Erika F. Augustine,Deborah Baker,Alicia Brocht,Cindy Casaceli,Ken Eaton,Sue Henderson,Nichole McMullen,Phounsavath Muneath,Laura Trusso,Carlinda Field,Saurav Brahmachari,Liana S. Rosenthal,Emily Carman,Cornelia Kamp,Patrick Bolger,Claire E. Wegel,Holly Reynolds,Oren A. Levy,Amber Servi,Kelvin L. Chou,Angela S Stovall,Gian Pal,Kellie Keith,Kathryn A. Chung,Joohi Shahed,Christine Hunter,Binit B. Shah,Katie Sullivan,Albert Y. Hung,Grace Bwala,Meredith Spindler,Alexandria Oliver,Robert A. Hauser,Claudia Rocha,Eric Molho,Sharon Evans,Holly A. Shill,Farah Ismail,Natividad Stover,Candace Cromer,Courtney Blair,Lin Zhang,Olga Kishchenko,Matthew Swan,Laura Ramirez,Samuel Frank,Stephanie Burrows,Andrew P. Duker,Christina Gruenwald,Karen Blindauer,Lynn Wheeler,Lauren Seeberger,Abigail Simpson,Burton L. Scott,Lisa Gauger,Anwar Ahmed,Yvette Pitchford,Jennifer Mule,Adolfo Ramirez-Zamora,Derek B. Ridgeway,John Slevin Slevin,Renee Wagner Wagner,Vanessa K. Hinson,Shonna Jenkins,John L. Goudreau,Doozie Russell,Zoltan Mari,Lilliana Dumitrescu,Jason Aldred,Melissa Bixby,Mark S. LeDoux +90 more
TL;DR: While nilotinib demonstrated acceptable safety and tolerability in this cohort, the low cerebrospinal fluid exposure, lack of biomarkers effects, and efficacy data trending in the negative direction indicate that further testing ofnilotinib in treatment of Parkinson disease is not warranted.
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
Michael A. Schwarzschild,Alberto Ascherio,Cindy Casaceli,Gary C. Curhan,Rebecca Fitzgerald,Cornelia Kamp,Codrin Lungu,Eric A. Macklin,Kenneth Marek,Dariush Mozaffarian,David Oakes,Alice Rudolph,Ira Shoulson,Aleksandar Videnovic,Burton L. Scott,Lisa Gauger,Jason Aldred,Melissa Bixby,Jill Ciccarello,Steven A. Gunzler,Claire Henchcliffe,Claire Henchcliffe,Matthew Brodsky,Kellie Keith,Robert A. Hauser,Christopher G. Goetz,Mark S. LeDoux,Vanessa K. Hinson,Rajeev Kumar,Alberto J. Espay,Joohi Jimenez-Shahed,Christine Hunter,Chadwick W. Christine,Aaron Daley,Maureen A. Leehey,J. Antonelle de Marcaida,Joseph H. Friedman,Albert Y. Hung,Grace Bwala,Irene Litvan,David Simon,Tanya Simuni,Cynthia Poon,Mya C. Schiess,Kelvin L. Chou,Ariane Park,Danish Bhatti,Carolyn Peterson,Susan R. Criswell,Liana S. Rosenthal,Jennifer Durphy,Holly A. Shill,Shyamal H. Mehta,Anwar Ahmed,Andres Deik,John Y. Fang,Natividad Stover,Lin Zhang,Richard B. Dewey,Ashley Gerald,James T. Boyd,Emily Houston,Valerie Suski,Sherri Mosovsky,Leslie J. Cloud,Binit B. Shah,Marie Saint-Hilaire,Raymond C. James,Sarah Elizabeth Zauber,Stephen G. Reich,David Shprecher,Rajesh Pahwa,April Langhammer,Kathrin LaFaver,Peter A LeWitt,Patricia Kaminski,John L. Goudreau,Doozie Russell,David J. Houghton,Ashley Laroche,Karen Thomas,Martha McGraw,Zoltan Mari,Carmen Serrano,Karen Blindauer,Marcie Rabin,Roger Kurlan,John C. Morgan,Michael Soileau,Melissa Ainslie,Ivan Bodis-Wollner,Ruth B. Schneider,Cheryl Waters,Amber Servi Ratel,Christopher A. Beck,Patrick Bolger,Katherine F. Callahan,Grace F. Crotty,David Klements,Melissa Kostrzebski,Gearoid M. McMahon,Lindsay Pothier,Sushrut S. Waikar,Anthony E. Lang,Anthony E. Lang,Tiago A. Mestre +105 more
TL;DR: A randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early Parkinson disease was conducted in this article, and the results showed no significant difference in the rate of clinical disease progression.
109